P53-binding protein 1 (53BP1) is a multi-faceted double-strand break (DSB) repair protein which transcends many fields 1,2 because it affects telomere dynamics, antibody genesis and efficacy of cancer therapy. It contributes to both the repair 3 and the orientation of the broken DNA ends 4 during class-switch recombination (CSR), and its loss almost completely abrogates CSR 5, 6 . The function of 53BP1 in the choice of DSB repair pathway is manifested in breast cancer associated gene 1 (Brca1)-deficient cells. Brca1-mutant cells are deficient in homologous recombination-mediated DSB repair and exquisitely sensitive to treatment with PARP inhibitors (PARPi) 7, 8 . Loss of 53BP1 restores homologous recombination in Brca1-mutant cells [9] [10] [11] , desensitizing them to PARPi. The minimal focus-forming region of 53BP1 (53BP1-FFR) required for localization of 53BP1 to DSBs includes an oligomerization domain, a tandem Tudor domain 12 and the ubiquitin-dependent recruitment (UDR) motif 13, 14 . The Tudor domain binds H4K20me2 (ref. 15) while UDR binds the mono-ubiquitylated lysine 15 of histone H2A
. The function of 53BP1 in the choice of DSB repair pathway is manifested in breast cancer associated gene 1 (Brca1)-deficient cells. Brca1-mutant cells are deficient in homologous recombination-mediated DSB repair and exquisitely sensitive to treatment with PARP inhibitors (PARPi) 7, 8 . Loss of 53BP1 restores homologous recombination in Brca1-mutant cells [9] [10] [11] , desensitizing them to PARPi. The minimal focus-forming region of 53BP1 (53BP1-FFR) required for localization of 53BP1 to DSBs includes an oligomerization domain, a tandem Tudor domain 12 and the ubiquitin-dependent recruitment (UDR) motif 13, 14 . The Tudor domain binds H4K20me2 (ref. 15) while UDR binds the mono-ubiquitylated lysine 15 of histone H2A 14 . In response to DSBs, ATM phosphorylates 53BP1 (refs 16, 17) and initiates a signalling cascade which leads to the RNF168-mediated ubiquitylation of chromatin in the vicinity of the DSB 18, 19 . Phosphorylation of 53BP1 and ubiquitylation of histone H2A are both DNA damage-dependent and are necessary for 53BP1 recruitment and retention at DSBs.
Here we describe a functionally uncharacterized protein, TIRR, that directly interacts with 53BP1 and regulates its recruitment to chromatin. TIRR (alias Syndesmos or Nudt16L1) has 46% sequence homology with Nudt16, a member of the nudix hydrolase family and associates with 21) . However, TIRR lacks enzymatic activity 22, 23 and its function in cells is unclear. We observe that TIRR directly interacts with the tandem Tudor domain of 53BP1, and the H4K20me2/Tudor interaction interface overlaps with that of TIRR/Tudor. Upon DNA damage, ATM-induced phosphorylation of 53BP1 and RIF1 recruitment are necessary for the dissociation of the TIRR-53BP1 complex. This allows 53BP1 localization to chromatin, and its function in DSB repair and CSR. Overexpression of TIRR blocks 53BP1 recruitment to DSBs and impairs CSR. Conversely, loss of TIRR destabilizes nuclear-soluble 53BP1 and the association of 53BP1 with its binding partners is altered in these cells. Thus, TIRR has a dual role in regulating 53BP1 function: first, by stabilizing 53BP1 and maintaining its sub-nuclear localization before DNA damage; second, by influencing the interaction of 53BP1 with effector proteins in response to DSBs.
TIRR as a new partner of 53BP1
To identify regulatory factors of 53BP1 recruitment to chromatin, proteins associated with 53BP1-FFR were analysed by mass spectrometry (Fig. 1a, b and Supplementary Table 1 ). On the basis of percentage of coverage (47.0%) and the number of unique peptides (14) , TIRR was one of the most abundant 53BP1-FFR binding partners. Reciprocally 53BP1 was co-purified with a tagged version of TIRR only in the nucleus (Fig. 1c, d ). Mass spectrometry analyses further confirmed the presence of 53BP1 within the TIRR nuclear complex together with established 53BP1 interacting proteins such as MDC1 (Supplementary Table 2 ). Moreover, endogenous 53BP1 and TIRR co-immunoprecipitated (Extended Data Fig. 1a) .
To investigate the 53BP1/TIRR interaction in intact cells, the LacO/ LacI tethering system was used 24 . TIRR was fused to the Escherichia coli lac-repressor (LacI) and tagged with Cherry-red fluorescent protein (mCherry-LacI-TIRR). mCherry-LacI-TIRR co-localized with endogenous 53BP1 in 57.5 ± 2% of the cells analysed (Fig. 1e) . Conversely, green fluorescent protein (GFP)-LacI-53BP1 co-localized
53BP1 Tudor domain interacts with TIRR
Next, to map the binding site of 53BP1 with TIRR, interaction of recombinant fragments of 53BP1-FFR and recombinant TIRR was assessed at different salt concentrations. TIRR interacted with the Tudor-UDR as well as with the tandem Tudor alone (Extended Data Fig. 1b, c) and it impaired the binding of the Tudor domain with an H4K20me2 peptide (Extended Data Fig. 1d, e) . Using isothermal titration calorimetry (ITC), we derived a dissociation constant (K d ) of 0.79 μM for the interaction of Tudor with TIRR (Extended Data Fig. 1f ). The ITC results are consistent with a 1:1 stoichiometry for the Tudor-TIRR complex, most likely corresponding to two Tudor molecules binding to one TIRR homodimer.
Binding surface of 53BP1 tandem Tudor for TIRR
We used nuclear magnetic resonance (NMR) spectroscopy to map the binding interface of TIRR on the tandem Tudor domain surface. Upon serial addition of unlabelled TIRR to 15 N HSQC spectrum were preferentially broadened at sub-stoichiometric amounts of TIRR (Fig. 2a) . These preferentially broadened signals belonged to residues mapping to one side of the tandem Tudor that includes the aromatic cage in the first Tudor domain which accommodates H4 dimethylated lysine 20 and to additional residues in the second Tudor domain (Fig. 2a, b) . Residues of 53BP1 for which signal intensities were preferentially decreased are similar to those affected by interaction with an H4K20me2 peptide, indicating that H4K20me2 and TIRR binding surfaces on Tudor overlap even if there is no H4-like motif in TIRR. The interaction with TIRR is, however, more extensive as it involves residues from the second Tudor domain which do not interact with H4K20me2 (Fig. 2a) . To extend this observation in cells, we tested Tudor domain mutants W1495A and D1521A that disrupt binding to H4K20me2 (ref. 15 ) and the phosphomimetic mutants S1609E/T1618D in the UDR motif that inhibits binding to H2AK15ub 25, 26 . As anticipated, these mutants did not form foci in response to ionizing radiation when transfected into U2OS cells (Fig. 2c) . Unlike the S1609E/T1618D mutant, the two Tudor mutants W1495A and D1521A impaired the interaction of 53BP1-FFR with TIRR. This suggested that the Tudor domain, in contrast to the UDR motif, is required for binding TIRR.
The binding interface of TIRR and 53BP1 Tudor
We also used NMR spectroscopy to probe the Tudor binding surface in TIRR. The standard 1 H-15 N TROSY HSQC approach could not be used owing to the high molecular mass of TIRR. Therefore, we initially investigated the changes in intensities in the 1 H-13 C heteronuclear multiple-quantum coherence (HMQC) spectrum of TIRR 13 C-dimethylated at lysine residues resulting from interaction with 53BP1 Tudor. While all 1 H- 13 C correlation signals in TIRR tended to decrease upon addition of Tudor, of the nine lysine residues, we noticed the preferential disappearance of signals assigned to K10 and K151, suggesting that these two amino acids are in the vicinity of the binding interface. This approach is difficult owing to extensive signal overlap. Nevertheless, we were able to confirm the preferential disappearance of K10 and K151 signals after selective installation of 13 C-labelled dimethyl-lysine analogues to generate TIRR proteins with K C 10me2, K C 151me2 and K C 205me2. For this approach, the two solvent-accessible cysteines in TIRR (C88 and C171) were replaced by serines. A partly buried cysteine (C28) was not mutated. Upon addition of 53BP1, there was preferential disappearance of K C 10me2 and K C 151me2 signals compared with K C 205me2, which was not affected by the interaction (Fig. 2d) . Unexpectedly, residue C28 was also modified (K C 28me2). While this complicates the analysis because the K C 28me2, K C 6me2 and K C 203me2 signals overlap, K C 28me2 also serves as an internal control (Fig. 2d) . We note that to interact with a single 53BP1 tandem Tudor, K10 and K151, which are far apart within one protomer, necessarily belong to two different protomers of the TIRR homodimer to be sufficiently close in space to both contact one Tudor molecule (Fig. 2e) . Having demonstrated that K10 and K151 were in the vicinity of the binding interface, we next asked whether these two residues were involved in the interaction with 53BP1 in cells. As shown in Fig. 2f , the mutation of these two lysine residues into glutamic acid (E) drastically reduced the interaction of TIRR with 53BP1 in undamaged U2OS cells. However, individual mutants revealed that K151E mutant continues to associate with 53BP1 in cells, while K10E mutation is sufficient to disrupt the interaction with 53BP1. We concluded that the residue K10 is crucial for the interaction with 53BP1.
TIRR impairs 53BP1 functions
Next, we tested whether TIRR interaction with the Tudor domains influences 53BP1 function. First, we observed that high TIRR expression almost completely abolishes 53BP1 foci formation (Fig. 3a) . Second, TIRR overexpression conferred resistance to the PARPi olaparib ( Fig. 3b) and restored homologous recombination in mouse embryonic fibroblasts (MEFs) carrying hypomorphic Brca1-Δ11 alleles (Extended Data Fig. 2a) . Furthermore, silencing 53BP1 in cells overexpressing TIRR showed the same extent of olaparib resistance as 53BP1-depleted cells, indicating that TIRR-induced olaparib resistance was probably mediated by loss of 53BP1 function. Finally, we tested whether TIRR compromised 53BP1 function in CSR of primary B cells. CSR to IgG1 was significantly reduced by TIRR ( Fig. 3c and Extended Data Fig. 2b) , and was not caused by reduced levels of activationinduced cytidine deaminase (AID) or expression of germline transcripts (Extended Data Fig. 2c, d ). Taken together, these data demonstrate that TIRR overexpression can radically impair the function of 53BP1 in DSB repair.
ATM activity disrupts 53BP1-TIRR complex
The interaction of 53BP1 and TIRR was reduced following ionizing radiation ( Fig. 4a) and this was not due to degradation of TIRR or 53BP1 (Extended Data Fig. 3a, b) . Consistent with this, TIRR is not recruited to sites of DNA damage induced by laser micro-irradiation 
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(Extended Data Fig. 3e ). The two TIRR residues K10 and K151 that belong to the interaction interface with 53BP1 ( Fig. 2) are constitutively ubiquitylated 27 ; however, the double TIRR mutant K151R/K10R dissociated from 53BP1 in response to damage (Extended Data  Fig. 3c ). More broadly, ionizing radiation did not alter the TIRR ubiquitylation level (Extended Data Fig. 3d ). We then focused on 53BP1 and observed that, unlike the full-length (FL) 53BP1 or the 53BP1 lacking the BRCT motif (ΔBRCT), the 53BP1-FFR did not dissociate from TIRR after ionizing radiation (Fig. 4b) . A deletion analysis revealed that a domain encompassing residues 200-700 was required for ionizing-radiation-mediated dissociation of 53BP1 from TIRR (Fig. 4b) .
The amino (N) terminus of 53BP1 contains 28 S/TQ consensus sites phosphorylated by ATM following ionizing radiation mediating the interaction with RIF1 (refs 28-32) and PTIP 33 (PAX transactivation domain-interacting protein). We observed that ATM inhibition (Fig. 4c) or deletion (Extended Data Fig. 4a ) impaired the ionizing-radiationinduced dissociation of TIRR from 53BP1. Dissociation was also impeded when the 28 S/TQ sites were mutated to alanine (ΔBRCT-28A) (Fig. 4d) . These results suggest that endogenous TIRR would preferentially block recruitment of the 53BP1ΔBRCT-28A mutant to DSB foci relative to its wild-type counterpart. Co-expression of GFP-53BP1ΔBRCT and mCherry-53BP1ΔBRCT-28A in RPE1 cells demonstrated that 53BP1ΔBRCT-28A indeed has limited ability to form foci (Fig. 4e) . Deletion of TIRR in these cells restores the ability of 53BP1ΔBRCT-28A to form foci at wild-type levels. Furthermore, introduction of exogenous TIRR selectively impaired the ability of 53BP1ΔBRCT-28A to form foci (Fig. 4e) . Collectively, our data suggest that DNA damage-dependent ATM phosphorylation of 53BP1 is required not only for the interaction with RIF1 and PTIP, but also to promote dissociation from TIRR.
53BP1 separation from TIRR requires RIF1
Since the N-terminal phosphorylation of 53BP1 recruits RIF1 and PTIP, we investigated whether these factors are involved in the ionizing-radiation-mediated disruption of the 53BP1-TIRR complex. Dissociation of the 53BP1-TIRR complex was selectively impaired by the depletion of RIF1 (Fig. 4f) and not by silencing PTIP (Extended Data Fig. 4b) . Consistent with this, depletion of RIF1 in RPE-1 and U2OS cells (Fig. 4g and Extended Data Fig. 4c, d ) and deletion of RIF1 in RPE1 cells significantly diminished the formation of 53BP1 foci at low doses (2 Gy and 4 Gy) and early time points (15 min and 30 min) after ionizing radiation (Extended Data Fig. 4e ). The effect was relatively mild in MEFs RIF1 −/− , indicating a potential species-specific difference (Extended Data Fig. 4f) . Furthermore, co-depletion of TIRR restored the formation of 53BP1 foci in RIF1-depleted cells (Fig. 4g) , suggesting that the impact of RIF1 loss on 53BP1 foci is due to the complex with TIRR. PTIP depletion had no effect on 53BP1 foci formation (Fig. 4g) . Together, these results suggest that RIF1 functions not only downstream of 53BP1 as an effector protein in DSB repair but also upstream to promote ionizing-radiation-induced 53BP1/TIRR dissociation and thereby facilitate 53BP1 recruitment to DSB sites.
TIRR regulates 53BP1 activity
TIRR depletion or deletion significantly reduced 53BP1 protein levels ( Fig. 5a and Extended Data Fig. 5a ). In TIRR-depleted cells the relatively soluble forms of 53BP1 (150 and 250 mM NaCl fractions) were destabilized ( Fig. 5b and Extended Data Fig. 5b) . Quantification of relative amounts of TIRR and 53BP1 also revealed that ~75% of TIRR was in the 150 and 250 mM NaCl fractions whereas only ~25% of 53BP1 was in these fractions (Extended Data Fig. 5c ). Consequently, in the absence of TIRR the proportion of 53BP1 in the 400 mM fraction (chromatin bound) is significantly increased. Consistent with these results, TIRR interacted almost exclusively with the soluble form of 53BP1 (Fig. 5b) . However, the total amount of TIRR and 53BP1 varied in different tumour lines (Extended Data Fig. 6a ), which could also impact sub-nuclear distribution of these proteins. Sucrose gradient fractionation of nuclear-soluble proteins in undamaged cells indicated that most 53BP1 co-sediments with TIRR (Extended Data Fig. 5d ). 
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Collectively, these results suggested that, in undamaged cells, the nuclearsoluble fraction of 53BP1 was stabilized through an interaction with TIRR. Next, we analysed 53BP1 binding partners by mass spectrometry in TIRR-deleted and GFP-TIRR-expressing cells after irradiation (Supplementary Table 3 ) and validated the results by immunoblot (Fig. 5c and Extended Data Fig. 7b ). In the absence of TIRR, there is a detectable increase in the association of 53BP1 with most of its well-characterized binding partners (such as MDC1, PTIP or KAP1) and an increase in ionizing-radiation-induced phosphorylation of 53BP1 on serines 25/29 and threonine 543 ( Fig. 5c and Extended Data Fig. 7b ). These differences were observed when TIRR-depleted cells were compared with the parental line (Extended Data Fig. 7b ) or with the TIRR-depleted cells in which TIRR was re-introduced (Fig. 5c) . Taken together our results demonstrate that TIRR depletion had a profound effect on the association of 53BP1 with multiple binding partners.
TIRR affects DNA damage sensitivity
We observed that TIRR depletion further sensitized Brca1-mutant MEFs and the Brca1-mutant human ovarian carcinoma lines COV362 and UWB289.1 to olaparib (Fig. 5d and Extended Data Fig. 8a, b) . These results phenocopied the 53BP1-dependent olaparib hypersensitivity induced by overexpressing RNF168 in Brca1-mutant MEFs 34 (Extended Data Fig. 8c ). TIRR depletion and RNF168 overexpression increased 53BP1 foci formation (Extended Data Fig. 5f ) and impaired RPA foci formation in Brca1-mutant MEFs (Fig. 5e, f) . Co-depletion of 53BP1 rescues all these phenotypes, suggesting a 53BP1-mediated impact of TIRR. Furthermore, we observed that deletion of TIRR (Extended Data Fig. 9a ) led to persistent DSBs and sensitized cells to radiation (Fig. 5g and Extended Data Fig. 9b, c) , and that this phenotype is 'rescued' by wild-type TIRR but not by the -TIRR mutant (K10E) that does not interact with 53BP1 (Fig. 5g) . Together, our results suggest that TIRR influences 53BP1 activity at multiple levels and broadly affects DSB repair efficiency in cells.
Discussion
Accumulation of 53BP1 at DSBs requires recognition of the constitutive and highly abundant histone modification H4K20me2 (ref. 35) . Selective unmasking of H4K20me2 occurs at DSB sites by removal of L3MBTL1 (ref. 36) and by the demethylase Jumonji domaincontaining protein 2A (JMJD2A) 37 along with concomitant deacetylation of H4K16 (ref. 38) . These represent indirect mechanisms restricting 53BP1 access to chromatin. Here we identify a direct regulatory step where TIRR binds the tandem Tudor domain of 53BP1 in the nuclearsoluble fraction to restrict its access to chromatin before DNA damage. Loss of TIRR leads to a hyperactivation of 53BP1 which pheno copies the overexpression/ectopic activation of RNF168 (refs 34, 39) . We speculate that a subset of chromatin-associated 53BP1 remains inactive in cells (not phosphorylated/no association with effectors), even after DNA damage. Ectopic activation of RNF168 or loss of TIRR activates this subset, leading to 'hyperactive' 53BP1 (see model in Extended Data  Fig. 10 ).
P53-binding protein 1 (53BP1) is a representative of Tudor domain-containing histone methyl-lysine readers such as PHF20, SGF29, Spindlin1, UHRF1 and SHH1 (ref. 40) . These reader proteins are involved in the pathogenesis of various diseases, and identifying small molecules that inhibit interactions between histone methyllysine readers and their respective binding partners on chromatin has significant clinical relevance 41 . Here, with TIRR, we have the first example of a bona fide cellular inhibitor of a histone methyl-lysine reader. This is also a unique mechanism by which the activity of this class of proteins maybe broadly regulated. TIRR directly blocks the Tudor/ methyl-lysine interface, and this observation could be potentially used to identify factors that inhibit the methyl-lysine binding function of other Tudor proteins.
Many clinical trials are underway with PARPi 42, 43 and therefore resistance to PARPi is an emerging clinical problem 44 . Overexpression of TIRR causes PARPi resistance in BRCA1-deficient cells. A compilation of 50 studies in the Cancer Genome Atlas shows that the TIRR gene 
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extracts were prepared by digestion for 10 min at 37 °C of pre-extracted nuclear pellets with micrococcal nuclease (Sigma) in 0.34 M sucrose buffer (20 mM TrisHCl (pH 7.65), 15 mM KCl, 60 mM NaCl, 0.34 M sucrose) containing 2 mM CaCl 2 . The reaction was stopped by adding EGTA to a final concentration of 5 mM and cleared extracts were used for immunoprecipitation. Mass spectrometry identification of proteins was performed by the Taplin laboratory (Harvard Medical School, Boston, Massachusetts, USA). Preparation of recombinant proteins. Fusion proteins were expressed in E. coli strain BL21(pLysS) and induced overnight with 0.1 mM isopropyl-β-d-thiogalactoside (IPTG) at 16 °C. Cells were harvested and resuspended in buffer containing 500 mM NaCl, 20 mM Tris-HCl (pH 8.0), 5 mM DTT and protease inhibitor cocktail (Roche), except for TIRR-His where DTT was omitted. Cells were lysed by sonication and cleared extracts were incubated for 1 h at 4 °C with anti-Flag-(Sigma) or Ni-NTA agarose resin (Life Technologies) to purify Flag-or His-fusion proteins, respectively. Proteins were eluted in lysis buffer containing 0.4 mg/ml of Flag peptide (Sigma) (Flag proteins) or 250 mM imidazole (His proteins) and dialysed in 50 mM Tris-HCl (pH 7.5), 150 mM NaCl and 10% glycerol. For NMR spectroscopy and ITC measurements, TIRR-His was treated with benzonase (EMD Millipore) after cell lysis and, upon binding to Ni-NTA resin, was extensively washed with 50 mM sodium phosphate (pH 7.5), 20 mM imidazole and 1 M NaCl to remove nucleic acids bound to the protein. TIRR was further purified by size-exclusion chromatography using a HiLoad 16/60 Superdex 75 column (GE Healthcare) and 50 mM sodium phosphate (pH 7.5), 500 mM NaCl running buffer. 53BP1 was purified as previously reported 15, 38 .
Isothermal titration calorimetry.
The ITC data were recorded at 25 °C using an iTC200 microcalorimeter (Malvern). TIRR in the calorimeter cell was at concentrations of 8-20 μM and 53BP1 tandem Tudor in the injection syringe was at concentrations of 0.1-0.4 mM. Protein samples were in 25 mM Tris-HCl (pH 7.5), 500 mM NaCl. NMR spectroscopy. The NMR data were recorded at 25 °C using a Bruker Avance III 700 MHz spectrometer equipped with a cryoprobe. Protein samples were in 50 mM sodium phosphate (pH 7.5), 500 mM NaCl and 10% D 2 O. 53BP1 tandem Tudor was 15 N-labelled using a previously reported procedure 15, 38 . For the titration experiments, TIRR concentrations ranged from 20 μM to 50 μM and small aliquots of 3.5 mM 53BP1 Tudor were added. All spectra were recorded using salt-tolerant shaped NMR tubes (Bruker). The reductive alkylation of TIRR to generate 13 C-dimethylated lysine residues followed a previously reported protocol making use of 13 C-enriched formaldehyde (Sigma) 46, 47 . The lysine residues were assigned by individual mutation to arginine. The synthesis of 13 C-methyl alkylation reagent dimethylated 2-chloroethylamine and installation of dimethylated lysine analogue followed previously reported protocols 47, 48 . Briefly, two of the three cysteines in TIRR were mutated into serines. Each lysine of interest (K10, K151 and K205) was replaced by a cysteine and converted to the dimethylated lysine analogues K C 10me2, K C 151me2 and K C 205me2. For the reductive alkylation of TIRR and the installation of dimethylated lysine analogues, excess reagent was eliminated by size-exclusion chromatography using a Superdex 75 10/300 GL column (GE healthcare) and 50 mM sodium phosphate (pH 7.5), 500 mM NaCl running buffer. The NMR data were processed with NMRPipe 49 and analysed with NMRView 50 . PyMol was used to create the molecular representations (WF Delano, The PyMOL Molecular Graphics System, version 1.3r1 (Schrodinger, New York, 2010)). TIRR and 53BP1 quantification. Purified TIRR and 53BP1 (amino acid 1220-1710 fragment) at ~2.5 μg/μl and 125 ng/μl, respectively, were reduced with 10 mM DTT and alkylated with 15 mM iodoacetamide before methanol chloroform precipitation followed by digestion with trypsin. Peptides were de-salted on homemade C18 StageTips and analysed by LC-MS/MS on an Orbitrap Fusion Lumos mass spectrometer (Thermo Fisher Scientific) to identify a set of target peptides for the analysis of samples. Peptides were separated on a 35 cm microcapillary column with a 100 μm inner diameter and packed with ~0.5 cm Magic C4 resin (5 μm, 100 Å, Michrom Bioresources) and Accucore C18 resin (2.6 μm, 150 Å, Thermo Fisher Scientific). A sample of about 4 μl was loaded onto the column for each analysis and separated using a 40 min gradient of 7-26% acetonitrile in 0.125% formic acid with a flow rate of 625 nl/min. MS1 spectra were acquired with the following parameters: resolution 120,000, scan range 400-1,500 Thomson (Th), automatic gain control (AGC) target 4 × 10 5 , maximum injection time 50 ms, and centroid spectrum data type. Dynamic exclusion was set with exclusion after one time with an exclusion duration of 60 s. MS2 spectra were acquired with CID and a resolution of 60,000, AGC 5 × 10 4 , maximum injection time 60 ms, isolation window 1.6 Th as centroid spectra. Raw files were converted into mzXML data type and searched using Sequest (against all human proteins reported by Uniprot) on an in-house data analysis tool developed by Steve P. Gygi (Harvard Medical School, Boston, Massachusetts, USA). Unique peptides were imported into Skyline 3.5.0.9319 and transition lists for heavy and light fragments exported for use on the mass spectrometer. Cells were grown in K8 Lys and lysed in hypotonic buffer (10 mM Tris (pH 7.65), 1.5 mM MgCl 2 , 10 mM KCl). Pellet nuclei were resuspended sequentially into 0.34 M sucrose buffer containing 150 mM, 250 mM and 400 mM NaCl. Extraction was performed for 10 min on a roller and nuclei were pelleted between each extraction by centrifugation at 800g. TIRR peptides for the different fractions were prepared as for the purified proteins above. For 53BP1, extracts were separated on 4-12% SDS-PAGE gels and the 53BP1 bands excised for in-gel digestion. Bands were reduced with 10 mM DTT and alkylated with 50 mM iodoacetamide. Gel pieces were washed and de-stained, dried and digested overnight in trypsin. Digests were de-salted on C18 StageTips. Combined samples of light reference peptides and heavy sample peptides were analysed by LC-MS/MS with the same MS1 settings as before, but without dynamic exclusion and targeting masses as determined and exported from Skyline 51 . MS2 spectra were collected at a resolution of 15,000, AGC 5 × 10 4 , maximum injection time 120 ms, isolation window 1.6 Th and as centroid spectra. Precursor and fragment ions were assessed in Skyline and ratios of the different fractions determined. TIRR and 53BP1 quantity were determined from the most abundant fraction (400 mM) and approximated for the other fractions. Pull-down assays. Pull-down of TIRR by 53BP1 truncation mutants was performed by incubating 1 μg of TIRR-His with 2 μg of Flag-fusion proteins immobilized on anti-Flag agarose resin in TGN buffer. After 2 h at 4 °C, beads were washed four times with TGN buffer containing either 200 or 400 mM NaCl and once with TGN buffer before elution of retained proteins with Laemmli sample buffer and analysis by immunoblotting. Peptide pull-downs were performed by incubating the indicated 53BP1 fragment protein with 2 μg of biotinylated histone H4-derived peptide in TNB buffer (50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.05% NP-40, 0.1% BSA). After 2 h at 4 °C, 10 μl of streptavidin-Dynabeads (Dynal) were added and the reaction was further incubated for 30 min at 4 °C. Beads were next treated as described above for pull-down of TIRR-His. Statistical analysis. Statistics were analysed with GraphPad (GraphPad Prism 5.0). Unless mentioned otherwise, all statistics were evaluated by two-tailed Student's t-test (Mann-Whitney test). No statistical methods were used to predetermine sample size. The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment. Data availability. The authors confirm that all relevant data are included in the paper and or its Supplementary Information files. 
